Supplementary Material for: Decreased Lactococcus lactis and propionic acid in feces of patients with Moyamoya disease: Possible implications of immune dysregulation by figshare admin karger (2628495)

“…The gut microbiota produces short-chain fatty (SCFA) and organic acids, influencing immune regulation and vascular remodeling. We aimed to characterize the gut microbiota in patients with MMD. …”

<i>SLC2A2</i> is essential for liver differentiation in developing vertebrates by Yejin Kim (740789)

“…The mRNA expression levels were normalized to β-actin. A significant increase (p-value < 0.001, ***) in igf1r expression was observed in <i>SLC2A2</i> MO-injected embryos compared to the control group. …”

Variations in the prevalence of OASI in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

Trends in the characteristics of women giving birth vaginally in France between 2010 and 2021. by Raphaele Houlbracq (20558509)

Subjects:

Variations in the prevalence of episiotomy in France between 2010 and 2021 according to the classification for episiotomy practices. by Raphaele Houlbracq (20558509)

Subjects:

pmed.1004501.t001 - Episiotomies and obstetric anal sphincter injuries following a restrictive episiotomy policy in France: An analysis of the 2010, 2016, and 2021 National Perinat... by Raphaele Houlbracq (20558509)

Subjects:

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx by Tengxiang Zhao (20749475)

“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”

BT9 did not improve survival in the orthotopic xenograft model of D425 medulloblastoma. by Zahra Motahari (6814013)

Subjects:

The effect of MAGMAS inhibition on mitochondrial respiration and acidification rate in D425 cells. by Zahra Motahari (6814013)

Subjects:

PAM16 correlation with N-MYC. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition on mitochondrial activity in medulloblastoma cells. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition reduces DAOY cells migration. by Zahra Motahari (6814013)

Subjects:

MAGMAS inhibition induces medulloblastoma cell death. by Zahra Motahari (6814013)

Subjects:

BT9 reduces DAOY and D425 medulloblastoma cell invasion. by Zahra Motahari (6814013)

Subjects:

Expression of MAGMAS in medulloblastoma. by Zahra Motahari (6814013)

Subjects:

BT9 exhibits a dose- and time-dependent cytotoxic effect on medulloblastoma. by Zahra Motahari (6814013)

Subjects:

Consecutive time points of data collection. by Martin Matzka (2636344)

“…Effect sizes expectedly decreased over time. Physical quality of life remained relatively constant over time and was the only outcome for which social integration on admission was not a significant prognostic factor.…”

Flow chart of study sample. by Martin Matzka (2636344)

“…Effect sizes expectedly decreased over time. Physical quality of life remained relatively constant over time and was the only outcome for which social integration on admission was not a significant prognostic factor.…”

OPV coverage by nationwide and at study areas (as per enrollment period). by Zahid Hasan Khan (6281396)

Subjects: